Irene Romera
About
Irene Romera is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Surgery.
According to data from OpenAlex, Irene Romera has authored 36 papers receiving a total of 641 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Endocrinology, Diabetes and Metabolism, 15 papers in Pharmacology and 11 papers in Surgery. Recurrent topics in Irene Romera's work include Diabetes Treatment and Management (22 papers), Treatment of Major Depression (12 papers) and Diabetes Management and Research (11 papers). Irene Romera is often cited by papers focused on Diabetes Treatment and Management (22 papers), Treatment of Major Depression (12 papers) and Diabetes Management and Research (11 papers). Irene Romera collaborates with scholars based in Spain, United States and Germany. Irene Romera's co-authors include Inmaculada Gilaberte, Pepa Polavieja, Víctor Pérez, Luis Caballero, José M. Menchón, Teresa Pérez, Jesús Reviriego, Ana María Cebrián Cuenca, Fernando Gómez‐Peralta and Fernando Álvarez Guisasola and has published in prestigious journals such as Journal of the American College of Cardiology, Journal of Affective Disorders and Psychiatry Research.
In The Last Decade
Irene Romera
35 papers receiving 611 citations
Peers
Irene Romera
Larissa L. Loukianova United States
Dieter Schoepf Germany
Margarida García-García Spain
André Tapp United States
James M. Eudicone United States
Anita S. Kablinger United States
Pilar Sierra Spain
R. Tepner United States
Maxime Barakat Canada
Nikhil Nihalani United States
Citations per year, relative to Irene Romera Irene Romera (= 1×)
peers
Larissa L. Loukianova
Countries citing papers authored by Irene Romera
Since
Specialization
Citations
This map shows the geographic impact of Irene Romera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irene Romera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irene Romera more than expected).
Fields of papers citing papers by Irene Romera
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Irene Romera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irene Romera. The network helps show where Irene Romera may publish in the future.
Co-authorship network of co-authors of Irene Romera
This figure shows the co-authorship network connecting the top 25 collaborators of Irene Romera. A scholar is included among the top collaborators of Irene Romera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irene Romera. Irene Romera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Díaz‐Cerezo, Silvia, et al.. (2025). Glycaemic and Weight Control in People Aged 65 or Younger Newly Diagnosed with Type 2 Diabetes in Spain: Insights from the PRIORITY-T2D Study. Advances in Therapy. 42(7). 3354–3368.
2.
Romera, Irene, et al.. (2025). The Association Between HbA1c Levels and the Risk of Myocardial Infarction and Stroke in People with Type 2 Diabetes: A Post Hoc Analysis of the REPRESENT Study. Diabetes Therapy. 16(6). 1229–1239.
3.
Pérez, Antonio Montes, et al.. (2023). Disease and Economic Burden of Poor Metabolic and Weight Control in Type 2 Diabetes in Spain: A Systematic Literature Review. Diabetes Therapy. 15(2). 325–341.
4.
Górriz, José Luis, et al.. (2022). Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. Diabetes Therapy. 13(3). 389–421.
5.
Romera, Irene, et al.. (2022). A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study. Advances in Therapy. 39(8). 3589–3601.
6.
Jódar, Esteban, Irene Romera, Qianqian Wang, Sarah L. Roche, & Luis‐Emilio García‐Pérez. (2021). Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials. Diabetes Obesity and Metabolism. 24(4). 631–640.
7.
Artime, Esther, Irene Romera, Silvia Díaz‐Cerezo, & Elías Delgado. (2021). Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review. Diabetes Therapy. 12(6). 1631–1659.
8.
Duque, Natalia, Esther Artime, Irene Romera, et al.. (2021). Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study. Advances in Therapy. 38(7). 3857–3871.
9.
Romera, Irene, Ignacio Conget, Luis Alberto Vázquez, et al.. (2020). Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c. Journal of Diabetes and its Complications. 34(7). 107575–107575.
10.
Romera, Irene, Ana María Cebrián Cuenca, Fernando Álvarez Guisasola, Fernando Gómez‐Peralta, & Jesús Reviriego. (2018). A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes Therapy. 10(1). 5–19.
11.
Ampudia‐Blasco, Francisco Javier, et al.. (2017). Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?. International Journal of General Medicine. Volume 10. 23–26.
12.
Romera, Irene, et al.. (2016). Eficacia y seguridad de empagliflozina en combinación con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2. Endocrinología y Nutrición. 63(10). 519–526.
13.
Romera, Irene, Víctor Pérez, Deborah Quail, et al.. (2014). Individual residual symptoms and functional impairment in patients with depression. Psychiatry Research. 220(1-2). 258–262.
14.
Romera, Irene, Víctor Pérez, Antonio Ciudad, et al.. (2013). Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis. BMC Psychiatry. 13(1). 51–51.
15.
Romera, Irene, Víctor Pérez, José M. Menchón, et al.. (2012). Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: A double-blind randomized study. Journal of Affective Disorders. 143(1-3). 47–55.
16.
Gilaberte, Inmaculada, Irene Romera, Víctor Pérez, José M. Menchón, & Alexander Schacht. (2012). Different levels of lack of improvement at 4 weeks of escitalopram treatment as predictors of poor 8-week outcome in MDD. Journal of Affective Disorders. 146(3). 433–437.
17.
Romera, Irene, Ángel L. Montejo, Fernando Caballero, et al.. (2010). Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: Prevalence of painful somatic symptoms, functioning and health status. Journal of Affective Disorders. 127(1-3). 160–168.
18.
Romera, Irene, Víctor Pérez, José M. Menchón, Pepa Polavieja, & Inmaculada Gilaberte. (2010). Optimal cutoff point of the Hamilton Rating Scale for Depression according to normal levels of social and occupational functioning. Psychiatry Research. 186(1). 133–137.
19.
Romera, Irene, et al.. (2009). Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study. European Psychiatry. 25(1). 58–65.
20.
Zoreda, Luís Caballero, Enric Aragonès, Javier Garcı́a-Campayo, et al.. (2008). Prevalence, Characteristics, and Attribution of Somatic Symptoms in Spanish Patients With Major Depressive Disorder Seeking Primary Health Care. Psychosomatics. 49(6). 520–529.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Larissa L. Loukianova Breakdown of academic impact, for papers by Dieter Schoepf Breakdown of academic impact, for papers by Margarida García-García Breakdown of academic impact, for papers by André Tapp Breakdown of academic impact, for papers by James M. Eudicone Breakdown of academic impact, for papers by Anita S. Kablinger Breakdown of academic impact, for papers by Pilar Sierra Breakdown of academic impact, for papers by R. Tepner Breakdown of academic impact, for papers by Maxime Barakat Breakdown of academic impact, for papers by Nikhil Nihalani